伊沙妥昔单抗联合硼替佐米、来那度胺和地塞米松治疗不适合或无意立即进行自体干细胞移植的新诊断多发性骨髓瘤患者的疗效与安全性
这项1b期研究评估了伊沙妥昔单抗联合硼替佐米-来那度胺-地塞米松(Isa-VRd)用于不适合或无意立即进行自体干细胞移植的新诊断多发性骨髓瘤患者。73例患者接受4个6周诱导周期Isa-VRd后接受Isa-Rd维持治疗。在疗效人群(n=71)中,总缓解率为98.6%,56.3%达到完全缓解或更好,50.7%达到微小残留病阴性(10^-5灵敏度)。
要点
- Isa-VRd在疗效人群(n=71)中总缓解率达98.6%,56.3%达完全缓解或更好。
- 36/71(50.7%)患者达到微小残留病阴性(10^-5灵敏度)。
- 79.5%(58/73)患者发生≥3级治疗中出现的不良事件,19.2%(14例)因不良事件永久终止研究治疗。
核心结论
- 这些数据支持在初诊多发性骨髓瘤中进一步研究伊沙妥昔单抗,例如3期IMROZ研究(Isa-VRd对比VRd)。
研究设计与样本
- 这项1b期研究(NCT02513186)评估了伊沙妥昔单抗联合硼替佐米-来那度胺-地塞米松(Isa-VRd)在不适合或无意立即进行自体干细胞移植的新诊断多发性骨髓瘤患者中的初步疗效、安全性和药代动力学。
- 共73例患者接受4个6周诱导周期Isa-VRd,随后接受4周周期的Isa-Rd维持治疗。
- 疗效人群为71例患者。
主要发现
- 在疗效人群(n=71)中,总缓解率为98.6%,56.3%达到完全缓解或更好(sCR/CR)。
- 36/71(50.7%)患者达到微小残留病阴性(10^-5灵敏度)。
- 79.5%(58/73)患者发生≥3级治疗中出现的不良事件,14例(19.2%)患者报告导致永久终止研究治疗的不良事件。
- 伊沙妥昔单抗的药代动力学参数在既往报道范围内,提示VRd不改变伊沙妥昔单抗的药代动力学。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with newly diagnosed multiple myeloma (NDMM) ineligible for autologous stem cell transplantation (ASCT) have lower survival rates and may benefit from frontline regimens that include novel agents. This Phase 1b study (NCT02513186) evaluated preliminary efficacy, safety, and pharmacokinetics (PK) of isatuximab, an anti-CD38 monoclonal antibody, combined with bortezomib-lenalidomide-dexamethasone (Isa-VRd) in patients with NDMM ineligible for/with no intent for immediate ASCT. Overall, 73 patients received four 6-week induction cycles of Isa-VRd, then maintenance with Isa-Rd in 4-week cycles. In the efficacy population (n = 71), the overall response rate was 98.6%, with 56.3% achieving a complete response or better (sCR/CR), and 36/71 (50.7%) patients reaching minimal residual disease negativity (10-5 sensitivity). Grade ≥3 treatment-emergent adverse events (TEAEs) occurred in 79.5% (58/73) of patients but TEAEs leading to permanent study treatment discontinuation were reported in 14 (19.2%) patients. Isatuximab PK parameters were within the previously reported range, suggesting that VRd does not alter the PK of isatuximab. These data support additional studies of isatuximab in NDMM, such as the Phase 3 IMROZ study (Isa-VRd vs VRd).
引用
- Ocio EM, Perrot A, Bories P, et al. Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible/with no immediate intent for autologous stem cell transplantation. Leukemia. 2023. PMID: 37316728. doi:10.1038/s41375-023-01936-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。